Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

NCT02807233 ·Status: COMPLETED

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

NCT00216398 ·Status: COMPLETED ·Phase: PHASE4

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

NCT00690898 ·Status: COMPLETED ·Phase: PHASE3

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

NCT02396953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

NCT04003519 ·Status: WITHDRAWN

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

NCT00444873 ·Status: COMPLETED ·Phase: PHASE3

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

NCT03158090 ·Status: RECRUITING

Somatuline Autogel: Acromegaly Self/Partner Injection Study

NCT00149188 ·Status: COMPLETED ·Phase: PHASE4

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

NCT00701363 ·Status: COMPLETED ·Phase: PHASE4

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

NCT00145405 ·Status: COMPLETED ·Phase: PHASE4

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

NCT00627796 ·Status: COMPLETED ·Phase: PHASE4

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

NCT00993356 ·Status: UNKNOWN ·Phase: PHASE2

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

NCT00383708 ·Status: COMPLETED ·Phase: PHASE3

Lanreotide Levels in Acromegaly

NCT00916916 ·Status: UNKNOWN

One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

NCT01471405 ·Status: COMPLETED

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

NCT01618513 ·Status: COMPLETED ·Phase: PHASE4

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

NCT05184231 ·Status: WITHDRAWN

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

NCT00128232 ·Status: COMPLETED ·Phase: PHASE3

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

NCT01995734 ·Status: APPROVED_FOR_MARKETING

Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

NCT02698384 ·Status: TERMINATED

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

NCT00686348 ·Status: COMPLETED

Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

NCT02396966 ·Status: COMPLETED

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

NCT00225979 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

NCT00616551 ·Status: COMPLETED ·Phase: PHASE3